(AOF) – TME Pharma announces that the final median overall survival for patients with recently diagnosed glioblastoma (brain cancer) treated with its product NOX-A12 has reached 19.9 months. The biotech specifies that this level surpasses all relevant competing therapeutic trials and announces that it has submitted to the FDA a clinical trial application and a request to obtain Fast Track designation, two requests which should be completed before the end of March 2024.
The objective is to have an FDA-approved clinical trial protocol in glioblastoma as well as access to an accelerated regulatory pathway in order to “maximize the chances of obtaining the necessary funding for the clinical trial at come via partnership, investment or other types of strategic operations.”
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.